<DOC>
	<DOCNO>NCT01866033</DOCNO>
	<brief_summary>The purpose study ass absolute bioavailability oral PCI-32765 effect grapefruit juice absorption PCI-32765 healthy adult participant .</brief_summary>
	<brief_title>A Study Assess Absolute Bioavailability Oral PCI-32765 Effect Grapefruit Juice Bioavailability PCI-32765 Healthy Participants</brief_title>
	<detailed_description>This open-label ( identity assign study drug know ) , sequential 2-way crossover design , pharmacokinetic ( study body drug ) study assess absolute bioavailability oral ( mouth ) PCI-32765 effect grapefruit juice absorption PCI-32765 approximately 8 healthy adult participant . The duration study approximately 45 day ( screen , treatment , follow-up ) . All patient receive PCI-32765 560 mg ( Treatment A ) administer mouth first period Treatment B ( 560 mg administer mouth without grapefruit juice ) Treatment C ( 140 mg administer mouth grapefruit juice ) accord randomization schedule Periods 2 3 . Participants fast overnight least 10 hour prior study drug dosing . Participants stay study center pharmacokinetic sampling . Serial pharmacokinetic sample collect dose 72 hour dose safety monitor throughout study .</detailed_description>
	<criteria>Women must postmenopausal surgically sterile Men must agree use adequate contraception method study 3 month receive last dose study drug , donate sperm study 3 month receive last dose study drug Body mass index 18 30 kg/m2 body weight less 50 kg Blood pressure ( lie 5 minute ) 90 140 mmHg systolic high 90 mmHg diastolic History current clinically significant medical illness include ( limited ) cardiac arrhythmia cardiac disease , hematologic disease , coagulation disorder ( include abnormal bleeding blood dyscrasia ) , lipid abnormality , significant pulmonary disease , include bronchospastic respiratory disease , diabetes mellitus , renal hepatic insufficiency , thyroid disease , neurologic psychiatric disease , infection , history immune disorder ( eg , lupus , rheumatoid arthritis , psoriatic arthritis ) , illness investigator considers exclude participant could interfere interpretation study result Clinically significant abnormal value hematology , coagulation , PFA 100 , clinical chemistry , urinalysis screen Clinically significant abnormal physical examination , vital sign , 12 lead electrocardiogram screening Use aspirin , NSAIDs , thienopyridines , vitamin E supplement , fish oil , flax seed within 1 week PFA100 assay test screening Use prescription nonprescription medication ( include vitamin herbal supplement ) , except paracetamol , hormonal replacement therapy topical anesthetic ( intravenous administration ) , within 14 day first dose study drug schedule Use herbal supplement within 30 day first dose administration History drug alcohol abuse accord Diagnostic Statistical Manual Mental Disorders ( 4th edition ) ( DSMIV ) criterion within 2 year screen positive test result ( ) alcohol and/or drug abuse screen Day 1 treatment period History clinically significant allergy , especially know hypersensitivity intolerance sulfonamide betalactam antibiotic Known allergy study drug excipients formulation Donated blood blood product substantial loss blood ( 500 mL ) within 3 month first administration study drug intention donate blood blood product study Received experimental drug use experimental medical device within 1 month within period le 10 time drug 's half life , whichever longer , first dose study drug schedule Unable swallow solid , oral dosage form whole aid water If woman , pregnant , breastfeed plan become pregnant study Positive test human immunodeficiency virus 1 2 antibody , hepatitis B surface antigen , hepatitis C antibodies History smoking use nicotinecontaining substance within previous 2 month positive cotinine test Preplanned surgery procedure would interfere conduct study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>March 2014</verification_date>
	<keyword>Healthy volunteer</keyword>
	<keyword>PCI-32765</keyword>
	<keyword>PCI 45227</keyword>
	<keyword>13C6 PCI-32765</keyword>
	<keyword>Pharmacokinetic</keyword>
	<keyword>Bioavailability</keyword>
</DOC>